Profile
Sector:
HealthcareCountry:
United StatesIPO:
05 January 2017Website:
http://organogenesis.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 21:36:11 GMTDividend
Analysts recommendations
Institutional Ownership
ORGO Latest News
CANTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the Truist Securities MedTech Conference, which is being held at the InterContinental Boston in Boston, MA on Tuesday, June 18th. Management will participate in 1x1 meetings. There will be no formal presentation.
To put it charitably, the market wasn't impressed with the company's recent performance. They traded out of the stock following the publication of quarterly and annual results.
Organogenesis Holdings, Inc. (ORGO) Q4 2023 Earnings Call Transcript
Organogenesis (ORGO) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.06 per share a year ago.
CANTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that fourth quarter and fiscal year 2023 financial results will be reported after the market closes on Thursday, February 29th.
Does Organogenesis (ORGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does Organogenesis (ORGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Organogenesis (ORGO) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Organogenesis Holdings, Inc. (NASDAQ:ORGO ) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Gary Gillheeney - President, CEO & Chair David Francisco - CFO Conference Call Participants Ryan Zimmerman - BTIG Operator Welcome, ladies and gentlemen, to the Third Quarter of Fiscal Year 2023 Earnings Conference Call for Organogenesis Holdings Inc. [Operator Instructions]. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly.
Organogenesis focuses on advanced wound products. The company's second-quarter revenue and net income were down year over year.
What type of business is Organogenesis Holdings?
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
What sector is Organogenesis Holdings in?
Organogenesis Holdings is in the Healthcare sector
What industry is Organogenesis Holdings in?
Organogenesis Holdings is in the Drug Manufacturers - Specialty & Generic industry
What country is Organogenesis Holdings from?
Organogenesis Holdings is headquartered in United States
When did Organogenesis Holdings go public?
Organogenesis Holdings initial public offering (IPO) was on 05 January 2017
What is Organogenesis Holdings website?
https://organogenesis.com
Is Organogenesis Holdings in the S&P 500?
No, Organogenesis Holdings is not included in the S&P 500 index
Is Organogenesis Holdings in the NASDAQ 100?
No, Organogenesis Holdings is not included in the NASDAQ 100 index
Is Organogenesis Holdings in the Dow Jones?
No, Organogenesis Holdings is not included in the Dow Jones index
When does Organogenesis Holdings report earnings?
The next expected earnings date for Organogenesis Holdings is 09 August 2024